Design Therapeutics, Inc. financial data

Symbol
DSGN on Nasdaq
Industry
Pharmaceutical Preparations
Location
6005 Hidden Valley Road, Suite 110, Carlsbad, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 5, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.15K % +1.95%
Debt-to-equity 4.06 % -4.24%
Return On Equity -18.5 % +20.5%
Return On Assets -17.8 % +20.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 56.6M shares +1.13%
Common Stock, Shares, Outstanding 56.6M shares +1.15%
Entity Public Float 164M USD -56.1%
Common Stock, Value, Issued 6K USD 0%
Weighted Average Number of Shares Outstanding, Basic 56.6M shares +1.09%
Weighted Average Number of Shares Outstanding, Diluted 56.6M shares +1.09%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 44.6M USD -27.3%
General and Administrative Expense 18.8M USD -12.5%
Operating Income (Loss) -63.4M USD +23.5%
Net Income (Loss) Attributable to Parent -50.5M USD +32%
Earnings Per Share, Basic -0.89 USD/shares +33.6%
Earnings Per Share, Diluted -0.89 USD/shares +33.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 45.7M USD +68%
Marketable Securities, Current 215M USD -22%
Cash, Cash Equivalents, and Short-term Investments 261M USD -13.9%
Other Assets, Current 236K USD
Assets, Current 265M USD -13.5%
Property, Plant and Equipment, Net 1.73M USD -7.15%
Operating Lease, Right-of-Use Asset 2.58M USD -21.3%
Assets 270M USD -13.5%
Accounts Payable, Current 1.3M USD -32.5%
Employee-related Liabilities, Current 2.39M USD -0.87%
Accrued Liabilities, Current 5.1M USD -50.1%
Liabilities, Current 6.39M USD -47.3%
Operating Lease, Liability, Noncurrent 1.95M USD -28%
Liabilities 8.34M USD -43.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -217K USD +89.2%
Retained Earnings (Accumulated Deficit) -201M USD -33.7%
Stockholders' Equity Attributable to Parent 261M USD -12%
Liabilities and Equity 270M USD -13.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.4M USD +28.6%
Net Cash Provided by (Used in) Financing Activities 20M USD
Net Cash Provided by (Used in) Investing Activities 20.6M USD +4.48%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 56.6M shares +1.13%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 8.2M USD +255%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 45.7M USD +68%
Deferred Tax Assets, Valuation Allowance 42.4M USD +58.5%
Deferred Tax Assets, Gross 43.4M USD +55.3%
Operating Lease, Liability 2.7M USD -20%
Depreciation 143K USD +10.9%
Payments to Acquire Property, Plant, and Equipment 195K USD +124%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -48.7M USD +34.1%
Lessee, Operating Lease, Liability, to be Paid 3.04M USD -22.9%
Property, Plant and Equipment, Gross 3.08M USD +16.5%
Operating Lease, Liability, Current 757K USD +11.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 973K USD +2.96%
Lessee, Operating Lease, Liability, to be Paid, Year One 945K USD +2.94%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 341K USD -40.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 663K USD -31.9%
Deferred Tax Assets, Operating Loss Carryforwards 15.1M USD +23.2%
Unrecognized Tax Benefits 1.8M USD +93.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 663K USD -31.9%
Deferred Tax Assets, Net of Valuation Allowance 975K USD -16.5%
Share-based Payment Arrangement, Expense 12.4M USD -5.09%